西那卡塞特
拟钙质
钙敏感受体
继发性甲状旁腺功能亢进
甲状旁腺激素
内分泌学
内科学
甲状旁腺主细胞
肾脏疾病
甲状旁腺功能亢进
医学
甲状旁腺
化学
钙
作者
Ziad A. Massy,Lucie Hénaut,Tobias E. Larsson,Marc G. Vervloet
标识
DOI:10.1016/j.semnephrol.2014.10.001
摘要
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease (CKD). Cinacalcet, an allosteric modulator of the calcium-sensing receptor (CaSR) expressed in parathyroid glands, is the only calcimimetic approved to treat SHPT in patients on dialysis. By enhancing CaSR sensitivity for plasma extracellular calcium (Ca(2+)0), cinacalcet reduces serum parathyroid hormone, Ca(2+)0, and serum inorganic phosphorous concentrations, allowing better control of SHPT and CKD-mineral and bone disorders. Of interest, the CaSR also is expressed in a variety of tissues where its activation regulates diverse cellular processes, including secretion, apoptosis, and proliferation. Thus, the existence of potential off-target effects of cinacalcet cannot be neglected. This review summarizes our current knowledge concerning the potential role(s) of the CaSR expressed in various tissues in CKD-related disorders, independently of parathyroid hormone control.
科研通智能强力驱动
Strongly Powered by AbleSci AI